- Home
- ICU vs PRPO Comparison
ICU vs PRPO Comparison
Compare ICU & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- PRPO
- Stock Information
- Founded
- ICU 2018
- PRPO N/A
- Country
- ICU United States
- PRPO United States
- Employees
- ICU N/A
- PRPO N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- ICU Health Care
- PRPO Industrials
- Exchange
- ICU Nasdaq
- PRPO Nasdaq
- Market Cap
- ICU 10.3M
- PRPO 9.5M
- IPO Year
- ICU N/A
- PRPO N/A
- Fundamental
- Price
- ICU $2.19
- PRPO $6.19
- Analyst Decision
- ICU
- PRPO
- Analyst Count
- ICU 0
- PRPO 0
- Target Price
- ICU N/A
- PRPO N/A
- AVG Volume (30 Days)
- ICU 24.8K
- PRPO 7.4K
- Earning Date
- ICU 11-13-2024
- PRPO 11-06-2024
- Dividend Yield
- ICU N/A
- PRPO N/A
- EPS Growth
- ICU N/A
- PRPO N/A
- EPS
- ICU N/A
- PRPO N/A
- Revenue
- ICU $68,000.00
- PRPO $17,411,000.00
- Revenue This Year
- ICU N/A
- PRPO $75.18
- Revenue Next Year
- ICU $344.44
- PRPO N/A
- P/E Ratio
- ICU N/A
- PRPO N/A
- Revenue Growth
- ICU N/A
- PRPO 31.31
- 52 Week Low
- ICU $1.88
- PRPO $4.31
- 52 Week High
- ICU $42.93
- PRPO $7.78
- Technical
- Relative Strength Index (RSI)
- ICU 25.85
- PRPO 45.83
- Support Level
- ICU $1.88
- PRPO $6.14
- Resistance Level
- ICU $2.81
- PRPO $6.47
- Average True Range (ATR)
- ICU 0.30
- PRPO 0.20
- MACD
- ICU -0.04
- PRPO 0.00
- Stochastic Oscillator
- ICU 18.58
- PRPO 38.42
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.